Premium
Double‐blind comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients
Author(s) -
Nyström C.,
Hällström T.
Publication year - 1985
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1985.tb02563.x
Subject(s) - maprotiline , reuptake inhibitor , serotonin , drug , antidepressant , anxiety , mood , serotonin uptake inhibitors , medicine , psychology , psychiatry , pharmacology , fluoxetine , receptor
– Seventy‐five outpatients with major depressive disorder (RDC) were randomly referred to treatment with a dominant serotonin (5‐HT) uptake inhibiting drug (zimeldine, 100 mg b.i.d.) or a dominant noradrenaline (NA) uptake inhibiting drug, (maprotiline, 75 mg b.i.d.). The total antidepressive effect was similar in the two groups for up to 4 weeks of treatment. Both drugs gave an effect on the depressive syndrome as a whole, with no preference for mood, anxiety, retardation or vital symptoms. Good response to the NA drug correlated to few prior episodes and few years since first episode, whereas the 5‐HT drug had its best effect when there were several previous episodes.